Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASPER: Low-dose Thymoglobulin for GVHD Prophylaxis in Elderly Haploidentical HSCT
NCT06066255Phase 2Not yet recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by Institut Paoli-Calmettes. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
antithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06066255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066255.